Alia Therapeutics is a biotechnology company dedicated to developing next-generation gene editing therapies for Inherited Retinal Diseases, starting with Retinitis Pigmentosa, a leading cause of inherited blindness worldwide
Alia Therapeutics is a biotechnology company dedicated to developing next-generation gene editing therapies for Inherited Retinal Diseases, starting with Retinitis Pigmentosa, a leading cause of inherited blindness worldwide. Alia addresses this challenge through a modular, mutation-agnostic approach enabled by its proprietary CRISPR platform.